Nonalcoholic steatohepatitis (NASH) may account for many cases of cryptogenic cirrhosis. If so, then steatosis might recur after liver transplantation. Two thousand fifty-two patients underwent primary liver transplantation for chronic liver disease between 1986 and 2004. Serial liver biopsy samples
Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis
β Scribed by Melissa J. Contos; Wendy Cales; Richard K. Sterling; Velimir A. Luketic; Mitchell L. Shiffman; A. Scott Mills; Robert A. Fisher; John Ham; Arun J. Sanyal
- Book ID
- 111723004
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 500 KB
- Volume
- 7
- Category
- Article
- ISSN
- 1527-6465
No coin nor oath required. For personal study only.
β¦ Synopsis
Many subjects with cryptogenic cirrhosis have underlying nonalcoholic steatohepatitis (NASH). The natural history of NASH-related cryptogenic cirrhosis after orthotopic liver transplantation (OLT) is not well defined. A primarily retrospective study of patients with the clinical histological phenotype of NASH-related cirrhosis undergoing OLT was performed. Data were compared with 2 sets of age-and weight-matched controls with (1) primary biliary cirrhosis or primary sclerosing cholangitis or (2) alcoholic liver disease. After OLT, all patients were managed by a standard immunosuppressive protocol. Liver biopsies were performed at 6 and 12 months after OLT and at 1-to 2-year intervals thereafter, as well as when liver enzyme levels were elevated enough to warrant diagnostic biopsy. Twenty-seven subjects with cryptogenic cirrhosis and a clinical histological phenotype of NASH and 3 patients with a long-standing diagnosis of NASH before OLT were included. The 30-day perioperative mortality was 1 in 30 patients. During a median follow-up of 3.5 Ψ 2.7 years, 2 additional patients died of sepsis. There was a timedependent increase in the risk for allograft steatosis that approached 100% by 5 years compared with only an approximately 25% incidence of steatosis in the control groups (P < .009, log-rank test). On multivariate analysis, only the cumulative steroid dose correlated with time to development of allograft steatosis. Three patients developed histological progression from hepatic steatosis to steatohepatitis. Of these, 1 patient developed progressive fibrosis. Four patients experienced at least 1 episode of acute cellular rejection; however, no patient developed chronic rejection or graft failure. In conclusion, nonalcoholic fatty liver disease occurs frequently after OLT in patients with the phenotype of NASH-related cirrhosis. Despite the frequent histological recurrence of disease, clinical outcomes are similar to those of other groups of patients undergoing OLT. (Liver Transpl 2001;7: 363-373.
π SIMILAR VOLUMES
Hepatic steatosis is a recognized problem in patients after orthotopic liver transplant (OLT). However, de novo development of nonalcoholic fatty liver disease (NAFLD) has not been well described. The aim of this study was to determine the prevalence and predictors of de novo NAFLD after OLT. A retr
Achieving long-term graft survival and mortality is the primary goal of liver transplantation (LT). However, disease recurrence remains a stumbling block, especially among patients with hepatitis C. In such patients, worse outcomes may be associated with comorbidities (i.e., hyperlipidemia, hyperten